| Primary Myelofibrosis
Inrebic vs Ojjaara
Side-by-side clinical, coverage, and cost comparison for primary myelofibrosis.Deep comparison between: Inrebic vs Ojjaara with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOjjaara has a higher rate of injection site reactions vs Inrebic based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Ojjaara but not Inrebic, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Inrebic
Ojjaara
At A Glance
Oral
Once daily
JAK2 inhibitor
Oral
Once daily
JAK1/JAK2 inhibitor
Indications
- Primary Myelofibrosis
- Post-polycythemia vera myelofibrosis
- Post-essential thrombocythemia myelofibrosis
- Primary Myelofibrosis
- Post-polycythemia vera myelofibrosis
- Post-essential thrombocythemia myelofibrosis
Dosing
Primary Myelofibrosis, Post-polycythemia vera myelofibrosis, Post-essential thrombocythemia myelofibrosis 400 mg orally once daily with or without food for patients with baseline platelet count >=50 x 10^9/L; thiamine prophylaxis 100 mg orally daily required during treatment.
Primary Myelofibrosis, Post-polycythemia vera myelofibrosis, Post-essential thrombocythemia myelofibrosis 200 mg orally once daily with or without food; swallow tablets whole.
Severe hepatic impairment (Child-Pugh Class C) Reduce starting dose to 150 mg orally once daily.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) diarrhea, nausea, anemia, vomiting, fatigue, thrombocytopenia, constipation
Serious cardiac failure, anemia, cardiogenic shock
Postmarketing uveitis
Most common (>=20%) Thrombocytopenia, diarrhea, hemorrhage, fatigue
Serious Bacterial infection, viral infection, hemorrhage, acute kidney injury, pneumonia, pyrexia, thrombosis, syncope, thrombocytopenia, renal and urinary tract infection
Postmarketing Hypersensitivity, erythema multiforme, toxic epidermal necrolysis
Pharmacology
JAK2-selective oral kinase inhibitor; fedratinib inhibits wild-type and mutationally activated JAK2 and FLT3, reducing STAT3/5 phosphorylation and blocking abnormal signaling associated with myeloproliferative neoplasms.
Momelotinib is a JAK1/JAK2 inhibitor that suppresses dysregulated JAK-STAT signaling in myelofibrosis and, via ACVR1 inhibition, reduces hepcidin expression to increase iron availability and red blood cell production.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Inrebic
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Ojjaara
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Inrebic
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (2/8)
Ojjaara
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Inrebic
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Ojjaara
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0
Bristol-Myers Squibb Patient Assistance Foundation (BMSPAF)Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableCancerCare: Myeloproliferative Neoplasms
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
InrebicView full Inrebic profile
OjjaaraView full Ojjaara profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.